Polyspecific malaria antibodies present at the time of infection inhibit the development of immunity to malaria but antibodies specific for the malaria merozoite surface protein, MSP1, facilitate immunity.
Serum taken from mice immune to malaria as a result of infection and drug cure, or from mice immunized with a recombinant form of the merozoite surface protein, MSP1, can provide passive protection of recipient mice against the lethal parasite, Plasmodium yoelii YM. However, recipients of MSP1-immune serum go on to develop long-term immunity, whereas recipients of serum from mice naturally immune to malaria rapidly lose their resistance to infection. We demonstrate that 'infection/cure' serum suppresses the development of both antibody and cell-mediated parasite-specific responses in recipients, whereas these develop in recipients of MSP1-specific antibodies. These data have profound implications for our understanding of the development of malaria immunity in babies who passively acquire antibodies from their mothers.
Zhang
Wenbao
W
The Cooperative Research Centre for Vaccine Technology, The Queensland Institute of Medical Research, Royal Brisbane Hospital, Queensland, Australia.
Liu
Xue Qin
XQ
Xu
Huji
H
Good
Michael F
MF
D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis*; D000918:Antibody Specificity; D015153:Blotting, Western; D007106:Immune Sera / Q000276:immunology; D007111:Immunity, Cellular; D007116:Immunization, Passive; D008288:Malaria / Q000276:immunology*; D020066:Merozoite Surface Protein 1 / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D010967:Plasmodium yoelii / Q000276:immunology*; D016052:Protozoan Vaccines / Q000276:immunology*; D013997:Time Factors; D014614:Vaccines, Synthetic / Q000276:immunology
D000913:Antibodies, Protozoan; D007106:Immune Sera; D020066:Merozoite Surface Protein 1; D016052:Protozoan Vaccines; D014614:Vaccines, Synthetic